308 related articles for article (PubMed ID: 17898861)
1. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
[TBL] [Abstract][Full Text] [Related]
2. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
[TBL] [Abstract][Full Text] [Related]
3. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
4. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
5. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
6. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
Agelaki S; Spiliotaki M; Markomanolaki H; Kallergi G; Mavroudis D; Georgoulias V; Stournaras C
Cancer Biol Ther; 2009 Aug; 8(15):1470-7. PubMed ID: 19483462
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling.
Yacoub A; McKinstry R; Hinman D; Chung T; Dent P; Hagan MP
Radiat Res; 2003 Apr; 159(4):439-52. PubMed ID: 12643788
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.
El Sheikh SS; Domin J; Abel P; Stamp G; Lalani el-N
Neoplasia; 2004; 6(6):846-53. PubMed ID: 15720812
[TBL] [Abstract][Full Text] [Related]
10. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
11. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
12. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
15. Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-kappa B activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway.
Mehta VB; Besner GE
J Immunol; 2005 Aug; 175(3):1911-8. PubMed ID: 16034135
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases.
LaMarca HL; Dash PR; Vishnuthevan K; Harvey E; Sullivan DE; Morris CA; Whitley GS
Hum Reprod; 2008 Aug; 23(8):1733-41. PubMed ID: 18487214
[TBL] [Abstract][Full Text] [Related]
17. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
18. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
[TBL] [Abstract][Full Text] [Related]
19. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
20. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]